Table 3.

Details of ongoing studies evaluating safety and efficacy of leflunomide and teriflunomide in COVID-19 (Data collected from Clinicaltrials.gov).

NCT no	Population	Intervention	Control	Outcome	Reference
NCT04361214/Phase 1/Single group trial	Mild COVID patients	Leflunomide	Single group study	Tolerability, Rate of hospitalization, Time to defervescence, Resolution of other COVID-19 symptoms	(University of Chicago, 2020)
NCT04532372/Phase 2/RCT	Severe COVID-19 in Patients With concurrent malignancy	Leflunomide	Placebo	Toxicity, time to clinical response, survival, O2 saturation improvement, SARS-CoV-2 resolution, hospitalization, requirement of mechanical ventilation.	(City of Hope Medical Center, 2021)
NCT04434118/Case control study	Rheumatoid Arthritis Patients on anti-rheumatoid drugs	Traditional anti-rheumatoid drugs	N.A.	Risk of SARS_CoV-2 infection among patients on different anti-rheumatoid drugs. Incidence of hospitalization.	(Abdallah, 2021)